Invasive fungal infections in renal transplant recipients

Experimental and Clinical Transplantation

Volumn 9, Issue 6, 2011, Pages 355-362

  Badiee, Parisa ^a   Alborzi, Abdolvahab ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antifungal agent; Galactomannan; Real time polymerase chain reaction; Renal transplant; Systemic mycosis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CALCINEURIN INHIBITOR; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ANTIGEN DETECTION; ASPERGILLOSIS; ASPERGILLUS; ASYMPTOMATIC DISEASE; CANDIDEMIA; CANDIDIASIS; CANDIDURIA; CLINICAL FEATURE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DERMATOPHYTOSIS; DIAGNOSTIC ACCURACY; DRUG ANTAGONISM; EARLY DIAGNOSIS; FUNGEMIA; FUNGUS CULTURE; GRAFT FAILURE; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT; LABORATORY TEST; LOADING DRUG DOSE; MICROBIOLOGICAL EXAMINATION; MOLECULAR DIAGNOSIS; MORTALITY; MUCORMYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SEROLOGY; SINGLE DRUG DOSE; SYMPTOM; SYSTEMIC MYCOSIS; TINEA VERSICOLOR;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS, INVASIVE; CRYPTOCOCCOSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MICROBIOLOGICAL TECHNIQUES; MUCORMYCOSIS; MYCOSES; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 83455197016     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Cohen SG, Greenberg MS. Rhinomaxillary mucormycosis in a kidney transplant patient. Oral Surg Oral Med Oral Pathol. 1980;50(1):33-38.
2. Usta M, Kahvecioglu S, Akdag I, et al. Aspergillus pneumonia in renal transplant recipients at a medical center in Turkey. Transplant Proc. 2004;36(9):2703-2707.
3. Tharayil John G, Shankar V, Talaulikar G, et al. Epidemiology of systemic mycoses among renal-transplant recipients in India. Transplantation. 2003;75(9):1544-1551.
4. Abbott KC, Hypolite I, Poropatich RK, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis. 2001;3(4):203-211.
5. Chan L, Gaston R, Hariharan S. Evolution of immunosuppression and continued importance of acute rejection in renal transplantation. Am J Kidney Dis. 2001;38(6 suppl 6):S2-S9.
6. Badiee P, Kordbacheh P, Alborzi A, Zeini F, Mirhendy H, Mahmoody M. Fungal infections in solid organ recipients. Exp Clin Transplant. 2005;3(2):385-389.
7. Nampoory MR, Khan ZU, Johny KV, et al. Invasive fungal infections in renal transplant recipients. J Infect. 1996;33(2):95-101.
8. Peterson PK, Ferguson R, Fryd DS, Balfour HH Jr, Rynasiewicz J, Simmons RL. Infectious diseases in hospitalized renal transplant recipients: a prospective study of a complex and evolving problem. Medicine (Baltimore). 1982;61(6):360-372.
9. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997;10(1):86-124.
10. Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant. 2006;20(4):401-409.
11. Einollahi B, Lessan-Pezeshki M, Pourfarziani V, et al. Invasive fungal infections following renal transplantation: a review of 2410 recipients. Ann Transplant. 2008;13(4):55-58.
12. Ergin F, Arslan H, Azap A, Demirhan B, Karakayali H, Haberal M. Invasive aspergillosis in solid-organ transplantation: report of eight cases and review of the literature. Transpl Int. 2003;16(4):280-286.
13. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32(3):358-366.
14. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis. 2001;7(3):375-381.
15. Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant. 2006;6(10):2365-2374.
16. Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis. 2009;200(6):1002-1011.
17. Chkhotua A, Yussim A, Tovar A, et al. Mucormycosis of the renal allograft: case report and review of the literature. Transpl Int. 2001;14(6):438-441.
18. Gupta KL. Fungal infections and the kidney. Indian J Nephrol. 2001;11:147-154.
19. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101-1011.
20. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-1821.
21. Badiee P, Alborzi A, Malekhosseini SA, Nikeghbalian S, Shakiba E. Determining the incidence of aspergillosis after liver transplant. Exp Clin Transplant. 2010;8(3):220-223.
22. Badiee P, Kordbacheh P, Alborzi A, Malekhoseini SA. Invasive fungal infection in renal transplant recipients demonstrated by panfungal polymerase chain reaction. Exp Clin Transplant. 2007;5(1):624-629.
23. Anaissie EJ, McGinnis MR, Pfaller MA, eds. Clinical Mycology. Philadelphia, PA: Churchill Livingstone; 2003:456.
24. Sandhu K, Gupta S, Kumar B, Dhandha R, Udigiri NK, Minz M. The pattern of mucocutaneous infections and infestations in renal transplant recipients. J Dermatol. 2003;30(8):590-595.
25. Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant. 2006;6(2):386-391.
26. Altiparmak MR, Apaydin S, Trablus S, et al. Systemic fungal infections after renal transplantation. Scand J Infect Dis. 2002;34(4):284-288.
27. Castaldo P, Stratta RJ, Wood RP, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg. 1991;126(2):149-156.
28. Virgili A, Zampino MR, La Malfa V, Strumia R, Bedani PL. Prevalence of superficial dermatomycoses in 73 renal transplant recipients. Dermatology. 1999;199(1):31-34.
29. Güleç AT, Demirbilek M, Seçkin D, et al. Superficial fungal infections in 102 renal transplant recipients: a case-control study. J Am Acad Dermatol. 2003;49(2):187-192.
30. Denning DW, Evans EG, Kibbler CC, et al. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology. Eur J Clin Microbiol Infect Dis. 1997;16(6):424-436.
31. Ahmadpour P, Lessan-Pezeshki M, Ghadiani MH, et al. Mucormycosis after living donor kidney transplantation: a multicenter retrospective study. Int J Nephrol Urol. 2009;1(1):39-44.
32. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore). 2000;79(4):250-260.
33. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44(3):373-379.
34. Khan ZU, Ahmad S, Mokaddas E, et al. Cerebral aspergillosis diagnosed by detection of Aspergillus flavus-specific DNA, galactomannan and (1-->3)-beta-D-glucan in clinical specimens. J Med Microbiol. 2007;56(pt 1):129-132.
35. Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med. 1988;108(1):88-100.
36. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis. 1991;164(4):731-740.
37. Horvath LL, Hospenthal DR, Murray CK, Dooley DP. Detection of simulated candidemia by the BACTEC 9240 system with plus aerobic/F and anaerobic/F blood culture bottles. J Clin Microbiol. 2003;41(10):4714-4717.
38. Sinha K, Tendolkar U, Mathur M. Comparison of conventional broth blood culture technique and manual lysis centrifugation technique for detection of fungemia. Indian J Med Microbiol. 2009;27(1):79-80.
39. Cray C, Watson T, Arheart KL. Serosurvey and diagnostic application of antibody titers to Aspergillus in avian species. Avian Dis. 2009;53(4):491-494.
40. Sendid B, Poirot JL, Tabouret M, et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol. 2002;51(5):433-442.
41. Bär W, Hecker H. Diagnosis of systemic Candida infections in patients of the intensive care unit. Significance of serum antigens and antibodies. Mycoses. 2002;45(1-2):22-28.
42. Persat F, Topenot R, Piens MA, Thiebaut A, Dannaoui E, Picot S. Evaluation of different commercial ELISA methods for the serodiagnosis of systemic candidosis. Mycoses. 2002;45(11-12):455-460.
43. Pinel C, Fricker-Hidalgo H, Lebeau B, et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol. 2003;41(5):2184-2186.
44. Sulahian A, Boutboul F, Ribaud P, Leblanc T, Lacroix C, Derouin F. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer. 2001;91(2):311-318.
45. Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol. 2007;45(6):1759-1765.
46. Van Burik JA, Myerson D, Schreckhise RW, Bowden RA. Panfungal PCR assay for detection of fungal infection in human blood specimens. J Clin Microbiol. 1998;36(5):1169-1175.
47. Badiee P, Alborzi A, Shakiba E, Ziyaeyan M, Pourabbas B. Molecular diagnosis of Aspergillus endocarditis after cardiac surgery. J Med Microbiol. 2009;58(pt 2):192-195.
48. Maaroufi Y, Heymans C, De Bruyne JM, et al. Rapid detection of Candida albicans in clinical blood samples by using a TaqMan-based PCR assay. J Clin Microbiol. 2003;41(7):3293-3298.
49. Badiee P, Alborzi A. Detection of Aspergillus species in bone marrow transplant patients. J Infect Dev Ctries. 2010;4(8):511-516.
50. Badiee P, Kordbacheh P, Alborzi A, et al. Study on invasive fungal infections in immunocompromised patients to present a suitable early diagnostic procedure. Int J Infect Dis. 2009;13(1):97-102.
51. Badiee P, Alborzi A, Vojdani R, et al. Early diagnosis of systemic candidiasis in bone marrow transplant recipients. Exp Clin Transplant. 2010;8(2):98-103.
52. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother. 2002;46(9):3091-3093.
53. Safdar N, Slattery WR, Knasinski V, et al. Predictors and outcomes of candiduria in renal transplant recipients. Clin Infect Dis. 2005;40(10):1413-1421.
54. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327-360.
55. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48(12):1743-1751.
56. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503-535.
57. Trullas JC, Cervera C, Benito N, et al. Invasive pulmonary aspergillosis in solid organ and bone marrow transplant recipients. Transplant Proc. 2005;37(9):4091-4093.
58. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291-322.
59. Lange DS, Richards HM, Guarnieri J, et al. Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 1998;39(6):944-950.
60. Gupta AK, Batra R, Bluhm R, Faergemann J. Pityriasis versicolor. Dermatol Clin. 2003;21(3):413-429, v-vi.
61. Bonifaz A, Saúl A. Comparative study between terbinafine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis. Eur J Dermatol. 2000;10(2):107-109.
62. Bourlond A, Lachapelle JM, Aussems J, et al. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol. 1989;28(6):410-412.
63. Panagiotidou D, Kousidou T, Chaidemenos G, et al. A comparison of itraconazole and griseofulvin in the treatment of tinea corporis and tinea cruris: a double-blind study. J Int Med Res. 1992;20(5):392-400.
64. Faergemann J, Mörk NJ, Haglund A, Odegård T. A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. Br J Dermatol. 1997;136(4):575-577.
65. Kohl TD, Martin DC, Nemeth R, et al. Fluconazole for the prevention and treatment of tinea gladiatorum. Pediatr Infect Dis J. 2000;19(8):717-722.